Impact BioMedical Inc. (NYSE American: IBO)’s Post

SFBN Feed: BridgeBio gathers investors to launch rare disease-focused spinoff https://lnkd.in/gQEigHGr The company earlier this year spun out a cancer-focused company with $200 million. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks #BayArea #SanFrancisco #Biotech #Lifescience #News

What is the key to building a successful biotech company? ✏️ 🚀 Building Success in Biotech: Key Strategies for Emerging Companies🚀 At Biovivium, we understand that the path to success in the biotech industry is paved with innovation, collaboration, and an unwavering commitment to quality. As we continue to grow and achieve new milestones, we want to share some of the fundamental strategies that have powered our journey and can inspire yours: 1. Innovation at the Core: Staying at the forefront of technological and scientific advancements is crucial. Innovate relentlessly, whether through pioneering research, product development, or adopting new technologies. 2. Strategic Partnerships: Collaborate with academic institutions, industry leaders, and technology providers. These partnerships can accelerate research, extend capabilities, and enhance market presence. 3. Robust Funding Strategies: Secure and strategically manage funding. Whether through venture capital, grants, or strategic investments, effective funding strategies are vital for sustained growth and research. 4. Regulatory Navigation: Understand and navigate the complex regulatory environment effectively. Ensuring compliance can not only mitigate risks but also speed up the time to market. 5. Talent Acquisition: Invest in attracting and retaining top talent. Skilled and motivated employees are the backbone of any successful biotech company. 6. Quality and Compliance: Never compromise on the quality of your research and products. Implementing rigorous QA, QC, and QMS processes ensures the safety, efficacy, and success of your products. 🌟 Join us at Biovivium as we continue to push the boundaries of what's possible in biotech. Together, we can transform innovative ideas into solutions that truly matter. 🔗 https://lnkd.in/eAxVGv8X #Biovivium #Biotechnology #Innovation #BiotechSuccess #HealthcareInnovation #StartupStrategy

📣 I had the great opportunity to follow the "Investing in Longevity (ILC)" course ! Designed for pharma executives 👩⚕️, biotechnology professional 👨🔬, venture capitalists 👨💼, and anyone interested in longevity tech invesment : 👉This course provides a comprehensive overview of the field, including the latest advances, key players, and potential risks and rewards developed by a multidisciplinary core team and key scientists as well as key opinion leaders in those fields. Highly recommend taking this course !!👍💯 Alex Zhavoronkov Evelyne Bischof, MD, PhD Phil Newman Ricardo Gaminha Pacheco #Aging #Longevity #Pharmaceuticals #Investors #venture #Biotech

STAT+: Biotech mogul Arie Belldegrun extends empire with launch of $600 million credit firm https://lnkd.in/gkNTPhsJ Biotech mogul Arie Belldegrun extends his empire with the launch of a $600 million credit firm. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News

Join us on June 7 for the next installment of our Startup & Accelerate webinar series. This session will focus on legal strategies and venture capital financing and market trends for biotechnology, medical device, and other life sciences emerging companies. Learn more and register: https://bit.ly/3V1GBAq #biotechnology #lifesciences

Venture philanthropy at work: 42 biotechnology companies Alzheimer's Drug Discovery Foundation supported with a total investment of $9.6 million have gone on to receive over $1 billion in follow-on commitments. Read: https://lnkd.in/dNdNTfp9

Biotechgate monthly report provides a summary of biotech financing in May 2024, highlighting trends, investment values, and notable funding rounds in the life science industry. In May 2024, private equity investment in the biotech sector saw a decline in both total value and number of financing rounds compared to April 2024, with notable variations across different regions. The sector's total investment value decreased from USD 3.3bn in April to USD 2.5bn in May, indicating a cautious approach or a possible reallocation of funds by investors. The number of financing rounds dropped slightly from 70 to 63, suggesting fewer investment opportunities or a more selective strategy. Most financing rounds in May 2024 continued to target US-based biotech companies, though there was a slight decrease in investment value (April: USD 2.6bn vs. May: USD 2.2bn) and a slight increase in the number of rounds (April: 31 vs. May: 35), indicating a broader spread of smaller investments. In Europe, the aggregated investment value decreased from USD 371m to USD 311m, with the number of rounds dropping from 20 to 18. The Rest of the World saw a significant decline in investment value from USD 329m to USD 174m, and the number of rounds fell from 21 to 12, highlighting a more pronounced pullback in investments outside the US. Funding rounds below USD 5m and those surpassing USD 30m each contributed almost equally to the total funding landscape, at 33% each. In terms of the allocation of funds for these deals, among deals over USD 30m, 5% were Seed rounds, 24% were Series A rounds, with Series B and C rounds each contributing 29%. For deals under USD 5m, 19% were Seed rounds, 24% were Series A, and 5% were Series B rounds. Additionally, transactions within the USD 5m to 15m range accounted for 22%, and rounds between USD 15 and 30m represented 11%. #biotech #biotechfunding #ipobiotech #healthcare #pharmainnovation https://lnkd.in/gibXmpCu

Exciting times in biotech! The first half of 2024 has seen near-record investment levels. Check out the EY German Biotechnology Report 2024 to see how we're part of this thriving sector.

#ICYMI our Chief Development Officer, Gilles Gallant, BPharm PhD FOPQ, joined industry leaders for Citeline Commercial’s roundtable at #BIO2024 exploring strategic practices, nuanced needs and key lessons for #biotech companies to consider when conducting #clinicaltrials.     Below, Dr. Gallant shares his insights on the value of diversifying clinical trials globally and maintaining a small, agile team to enhance operational efficacy and research outcomes. Check out additional highlights from the roundtable: https://bit.ly/4cmfzdw Biotechnology Innovation Organization

"Thrilled to be part of organizing the 3rd International Conference on Biotechnology! Honored to welcome esteemed doctors and scientists, pushing boundaries and shaping the future of biotech. Together, let's ignite innovation and pave the way for transformative discoveries! #BiotechConference #Innovation #ScienceLeaders"